Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Preempting and preventing drug-induced liver injury

Nature Genetics volume 42, pages 650–651 (2010)Cite this article

Subjects

A new study reports that susceptibility to drug-induced liver injury by the cyclooxygenase 2 (COX-2) inhibitor lumiracoxib is associated with a human lymphocyte antigen (HLA) class II haplotype. This finding suggests that those at risk of hepatotoxicity can be identified by HLA genotyping, raising the possibility that lumiracoxib can be resurrected as a useful drug.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Aithal, G.P. & Day, C.P. et al. Clin. Liver. Dis. 11, 563–575, vi–vii (2007).

    Article  Google Scholar 

  2. Goldkind, L. & Laine, L. et al. Pharmacoepidemiol. Drug Saf. 15, 213–220 (2006).

    Article  CAS  Google Scholar 

  3. Traversa, G. et al. Br. Med. J. 327, 18–22 (2003).

    Article  CAS  Google Scholar 

  4. Singer, J.B. et al. Nat. Genet. 42, 711–714 (2010).

    Article  CAS  Google Scholar 

  5. Kindmark, A. et al. Pharmacogenomics J. 8, 186–195 (2008).

    Article  CAS  Google Scholar 

  6. Daly, A.K. et al. Nat. Genet. 41, 816–819 (2009).

    Article  CAS  Google Scholar 

  7. Hautekeete, M.L. et al. Gastroenterology 117, 1181–1186 (1999).

    Article  CAS  Google Scholar 

  8. Donaldson, P.T. et al. J. Hepatol. (in the press) (2010).

  9. Donaldson, P.T. et al. Gut 53, 599–608 (2004).

    Article  CAS  Google Scholar 

  10. Schnitzer, T.J. et al. Lancet 364, 665–674 (2004).

    Article  CAS  Google Scholar 

  11. Farkouh, M.E. et al. Lancet 364, 675–684 (2004).

    Article  CAS  Google Scholar 

  12. Rubenstein, J.H. & Laine, L. et al. Aliment. Pharmacol. Ther. 20, 373–380 (2004).

    Article  CAS  Google Scholar 

  13. de Abajo, F.J., Montero, D., Madurga, M. & Garcia Rodriguez, L.A. Br. J. Clin. Pharmacol. 58, 71–80 (2004).

    Article  Google Scholar 

  14. Mallal, S. et al. N. Engl. J. Med. 358, 568–579 (2008).

    Article  Google Scholar 

  15. Hirata, K. et al. Pharmacogenomics J. 8, 29–33 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guruprasad P. Aithal is at the Nottingham Digestive Diseases Centre, National Institute for Health Research Biomedical Research Unit, Nottingham University Hospital National Health Service Trust, Nottingham, UK.,

    Guruprasad P Aithal

  2. Ann K. Daly is at the Institute of Cellular Medicine, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne, UK.,

    Ann K Daly

Authors
  1. Guruprasad P Aithal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann K Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann K Daly.

Ethics declarations

Competing interests

A.K.D. received funding from AstraZeneca and the International Serious Adverse Events Consortium. A.K.D. also consulted with Johnson and Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aithal, G., Daly, A. Preempting and preventing drug-induced liver injury. Nat Genet 42, 650–651 (2010). https://doi.org/10.1038/ng0810-650

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0810-650

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing